Welcome to ProTeamPhysicians.com
Log In Become a Member
   
Drugs
Analgesics
Anesthetics
Anti-infectives
Anti-
inflammatory
Anti-obesity
Cardiovascular agents
Cold and Flu
Diuretics
Gastro-
intestinal agents
Hormones
Nutritionals
Respiratory agents
Cardiovascular agents << back to Product News Brief
LOVENOX is approved for more indications in the United States than any other low molecular weight heparin (LMWH). It is the only one indicated for both outpatient and inpatient treatment of DVT when administered with warfarin sodium.

It is the only one proven more effective than heparin in Unstable Angina/Non-Q-Wave MI when administered with aspirin. Other indications include inpatient treatment of DVT with PE and DVT prophylaxis in: hip-and knee-replacement surgery; extended prophylaxis (3 weeks postdischarge) following hip-replacement surgery; abdominal surgery.

Contact Information
Medical sales:
Jason Lewis
Phone: 973-394-6577
Phone: 973-394-7388
jason.lewis@aventis.com
Contact Information
Medical services:
Rajalaxmi McKenna, M.D.
Senior Medical Product Leader
Phone: 973-394-7296
rajalaxmi.mckenna@aventis.com
www.lovenox.com

Additional Information
  • Lovenox Prescribing Information
  • Lovenox for Hip and Knee Replacement Surgery
  • Lovenox, when a Killer Clot Threatens


  • (If you don't have Adobe Acrobat, click here)